Turn Therapeutics Inc.
TTRX
$5.25
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 355.56% | 135.83% | -0.83% | -0.83% | -60.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 279.37% | 120.27% | 18.44% | 18.44% | -50.73% |
| Operating Income | -279.37% | -120.27% | -18.44% | -18.44% | 50.73% |
| Income Before Tax | -252.49% | -101.46% | -18.54% | -18.54% | 51.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -252.49% | -101.46% | -18.54% | -18.54% | 51.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -252.49% | -101.46% | -18.54% | -18.54% | 51.71% |
| EBIT | -279.37% | -120.27% | -18.44% | -18.44% | 50.73% |
| EBITDA | -288.33% | -123.59% | -17.82% | -17.82% | 51.39% |
| EPS Basic | -239.10% | -95.92% | -15.19% | -15.19% | 51.64% |
| Normalized Basic EPS | -239.76% | -95.65% | -16.33% | -16.33% | 51.74% |
| EPS Diluted | -239.10% | -95.92% | -15.19% | -15.19% | 51.64% |
| Normalized Diluted EPS | -239.76% | -95.65% | -16.33% | -16.33% | 51.74% |
| Average Basic Shares Outstanding | 3.73% | 2.67% | 2.64% | 2.64% | 0.02% |
| Average Diluted Shares Outstanding | 3.73% | 2.67% | 2.64% | 2.64% | 0.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |